바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.59 No.5
Citation Share

Comparison of Effect Between Thrombolysis and Anticoagulation in Major Pulmonary Thromboembolism

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2005, v.59 no.5, pp.487-496












& (2005). Comparison of Effect Between Thrombolysis and Anticoagulation in Major Pulmonary Thromboembolism. Tuberculosis & Respiratory Diseases, 59(5), 487-496.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : ‘Major pulmonary thromboembolism’ is defined as right ventricular (RV) dysfunction, with or without shock, accompanied by significant morbidity and mortality. In this study, those with major pulmonary thromboembolism were divided into the shock and RV dysfunction only groups, and then investigated the mortality and complications in thrombolysis or anticoagulation, respectively. Methods : In a retrospective study, between January 1995 and December 2004, 60 eligible patients with a major pulmonary thromboembolism, admitted in Asan Medical Center, were included. Results : A total of 57 patients were treated with medical therapy. Thrombolysis was performed in 13 patients (23%) and anticoagulation in 44 (77%). There were no differences in the APACHEⅡ and SOFA scores between the two groups. 6 (46%) and 11 (25%) patients died in the thrombolysis and anticoagulation groups, respectively (p=0.176). In the 19 patients (33%) showing shock, thrombolysis was performed in 9 (47%) and anticoagulation in 10 (53%). 4 (44%) of the 9 patients treated with thrombolytic agents and 3 (30%) of the 10 treated with anticoagulants died (p=0.650). In the 38 patients (67%) showing RV dysfunction only, thrombolysis was performed in 4 (11%) and anticoagulation in 34 (89%). 2 (50%) of the 4 patients treated with thrombolytics and 8 (24%) of the 34 treated with anticoagulants died (p=0.279). Three patients (23%) who underwent thrombolysis had a major bleeding episode, compared with 2 (5%) who were treated with anticoagulants (p=0.072). Conclusion: The results of our study showed that thrombolysis did not lower mortality and tended to increase major bleeding compared with anticoagulation in both the shock and RV dysfunction only groups. Further evaluation of the efficacy and safety of thrombolytic therapy for major thromboembolism appears warranted in Korea. (Tuberc Respir Dis 2005; 59: 487-496)

keywords
Major pulmonary thromboembolism, Thrombolysis, Anticoagulation RV dysfunction, Shock, Major pulmonary thromboembolism, Thrombolysis, Anticoagulation RV dysfunction, Shock

Reference

1.

(1991) A population-based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism:the Worcester DVT study,

2.

(1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry,

3.

(2003) The National survey of acute pulmonary thromboembolism in Korea,

4.

(1996) Predictors of in-hospital mortality in patients with acute massive pulmonary embolism results of the Management and Prognosis of Pulmonary Embolism Registry,

5.

(1977) Long-term prognosis of treated acute massive pulmonary embolism,

6.

(1997) Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism,

7.

(2000) Short-term clinical outcome of patients with pulmonary embolism,normal blood pressure and echocardiographic right ventricular dysfunction,

8.

(2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism:a meta-analysis of the randomized controlled trials,

9.

(2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism,

10.

(2001) Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation:results from a 128-patient monocenter registry,

11.

(2002) Thrombolysis vs heparin in the treatment of pulmonary embolism:a clinical outcome-based meta-analysis,

12.

(1997) The prevalence of Leiden mutation in the factor V gene in Korean patients suspected to have thrombosis,

13.

(1996) Lack of activation protein C resistance in healthy Hong Kong Chinese blood donors:correlation with absence of Arg506-Gln mutation of factor V gene,

14.

(1995) APC- resistance and Mnl I genotype(Gln 506. coagulation factor V are rare in Japanese population.,

15.

(2001) Clinical study of pulmonary thromboembolism,

16.

(1976) Mortality in patients treated for pulmonary embolism,

17.

(1999) Thrombolytic therapy of pulmonary embolism:a comprehensive review of current evidence,

18.

(1990) Tissue plasminogen activator for the treatment of acute pulmonary embolism,

19.

(1990) A randomized trial of single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism,

20.

(1992) PAIMS 2:alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism,

21.

(2004) Prevention of venous thromboembolism:the seventh ACCP conference on antithrombotic and thrombolytic therapy,

22.

(2000) Deep vein thrombosis after total hip replacement incidence and correlation between DVT and its risk factors,

23.

(1998) Comparative efficacy of a two- hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism:immediate clinical and hemodynamic outcome and one-year follow-up,

24.

(2000) Thrombolysis for acute pulmonary embolism in Chinese patients,

25.

(1997) Management strategies and determinants of outcome in acute major pulmonary embolism:results of multicenter registry,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy